Controversy Surrounding Fentanyl Distribution in New Mexico: DEA's Handling of Illicit Drug Sales and Public Safety Concerns
Federal authorities have chosen not to intervene in the distribution of illicit fentanyl pills in New Mexico, despite internal guidelines emphasizing public safety. The U.S. Drug Enforcement Administration denies participating in the practice of "walking" drugs, where agents allow drug deals to happen to catch higher-level traffickers. However, court records show that fentanyl sales continued in New Mexico without immediate action from the DEA or federal prosecutors. A whistleblower complaint filed by a DEA agent in Albuquerque revealed that over 300,000 fentanyl pills had made their way into the community. The Department of Justice's new protocol allows more discretion in allowing fentanyl "walking," prioritizing the success of criminal wiretap investigations over public safety concerns.
The investigation into the whistleblower complaint found that the agents and prosecutors in Albuquerque acted within their discretion and did not pose a substantial danger to public health and safety. The U.S. Attorney's Office in New Mexico stated that they prioritize removing fentanyl from the community while pursuing larger investigations to dismantle fentanyl distribution networks. Despite the DEA's insistence that no fentanyl sales were allowed to occur in wiretap cases in New Mexico, concerns remain about the quantities of fentanyl reaching the streets and contributing to drug overdose deaths.
Fentanyl remains a significant contributor to fatal drug overdoses nationwide, with New Mexico experiencing a high percentage increase in drug overdose deaths. Nonfatal suspected fentanyl overdoses treated in New Mexico emergency departments have also spiked. The whistleblower complaint highlighted instances where the DOJ's fentanyl protocol was ignored, leading to missed opportunities to prevent fentanyl distribution. The Office of Special Counsel defended the flexibility of prosecutors and investigators to choose operational approaches they deem most effective, even if it means not intervening in low-level suspects to avoid tipping off trafficking organizations.
The whistleblower, DEA agent David Howell, faced retaliation for his actions, including being prohibited from testifying in court and having his investigations not prosecuted by the U.S. Attorney's Office. Empower Oversight, a federal whistleblower protection organization, criticized the investigative report for downplaying the violations reported by Howell and excusing the fentanyl walking as a justified exercise of law enforcement discretion. Howell's case raises concerns about the balance between pursuing criminal investigations and protecting public safety in the fight against fentanyl distribution.